* Haemonetics Corp HAE.N HAE is expected to show a rise
in
quarterly revenue when it reports results on May 11.
* The Boston Massachusetts-based company is expected to
report a
9.3% increase in revenue to $289.643 million from $265 million a
year ago, according to the mean estimate from 5 analysts, based
on Refinitiv data.
* Refinitiv's mean analyst estimate for Haemonetics Corp is
for
earnings of 70 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Haemonetics
Corp
is $100, above its last closing price of $81.82.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Dec. 31 2022 0.83 0.80 0.85 Beat 5.9
Sep. 30 2022 0.68 0.67 0.83 Beat 23.2
Jun. 30 2022 0.51 0.51 0.58 Beat 13.6
Mar. 31 2022 0.60 0.60 0.65 Beat 8.2
Dec. 0.73 0.73 0.84 Beat 14.4
31 2021
Sep. 30 2021 0.61 0.61 0.60 Missed -1
Jun. 30 2021 0.45 0.45 0.50 Beat 11.1
Mar. 31 2021 0.67 0.67 0.46 Missed -31.5
This summary was machine generated May 9 at 10:02 GMT. All
figures in US dollars unless otherwise stated